spa – 第 6 页 – 爱上海419论坛-上海后花园论坛-夜上海论坛-上海龙凤419论坛

Which is the difference between Huawei p60 and p60pro／P60Art is worth starting with, parameter comparison

　　This article mainly introduces which Huawei P60, Huawei P60Pro, and Huawei P60Art are better, and the relevant information on the horizontal evaluation of the three mobile phones. Friends who need it can refer to it. I hope it will be helpful to everyone.

Which is the difference between Huawei p60 and p60pro/P60Art is worth starting with, parameter comparison

　　As we all know, the Huawei P60 series has been officially released at the end of March, bringing a total of three mobile phones: P60, P60 Pro, and P60 Art. All models have ushered in significant upgrades in communication, screen, image, body, etc., which has attracted the attention of many consumers. Although the configuration and pricing of the three models are different, due to the close size of the body and the close performance of the processor, many users have encountered difficulties in choosing and have asked questions: Which of the three Huawei P60 series models is the most worth buying?

　　Which one is better, Huawei P60 Pro or Huawei P60Art?

　　Objectively speaking, this year’s P60 standard version can be said to have ushered in the largest upgrade of the standard version in years, and maintained the same price. The screen parameters and body design are basically the same as those of the P60 Pro, making it the most cost-effective of the three models in the P60 series.

　　Compared with the previous generation model P50, Huawei P60 focuses on upgrading the core configuration such as performance, body, screen and image, and their parameters have been significantly improved compared with the P50, mainly including the following four major improvements:

　　Processor: Upgraded from Snapdragon 888 to Snapdragon 8 + Gen1 (3.0GHz version), power consumption issues are significantly improved, and the performance index is greatly improved.

　　Screen performance: Upgraded from a 6.5-inch 90Hz screen to a 6.67-inch 1-120Hz LTPO screen, the screen refresh rate has been upgraded by leaps and bounds.

　　Airframe design: Upgraded from the standard version of the simplified design to the Pro model, the fuselage design specifications and shape are almost exactly the same, and IP68 dust and water resistance is still supported.

　　Imaging experience: Upgraded from a regular 50MP main camera to a 48MP OIS main camera, and supports F1.4 to F4.0 variable aperture functions, significantly enhancing the imaging experience.

　　It can be seen that the Huawei P60 has brought a more obvious upgrade in terms of performance, screen, body and image compared to the P50, and the price is set to start at 4488 yuan. The operation of increasing the amount without increasing the price also allows the P60 to demonstrate a higher cost performance index.

　　In addition, compared with Huawei’s other flagship Mate 50 standard version, the Huawei P60 is equipped with a more advanced two-way satellite communication function, and the screen equipped with the Mate 50 is still a 90Hz refresh rate, compared with the 1-120Hz LTPO screen equipped with the P60. There is a significant performance gap, and the two mobile phones are currently priced relatively close. Obviously, the Huawei P60 has a higher cost performance.

　　Compared with the P60 Pro and P60 Art, the main differences between the Huawei P60 are reflected in the rear image configuration, Kunlun glass, and battery life charging. Their parameter differences are mainly reflected as follows:

　　The P60 adopts 48MP + 13MP + 12MP three-camera solution, and the telephoto solution is 12MP periscope head; it is equipped with 4815mAh battery + 66W fast charging + 50W wireless fast charging, and the screen adopts ordinary glass.

　　The P60 Pro adopts 48MP + 13MP + 48MP three-camera solution, and the telephoto solution is a 48MP super-concentrated night vision telephoto lens; it is equipped with 4815mAh battery + 88W fast charging + 50W wireless fast charging, and the screen adopts Kunlun glass.

　　P60 Art adopts 48MP + 40MP + 48MP three-camera solution, the telephoto solution is 48MP ultra-light-focusing night vision telephoto lens, and the ultra-wide-angle lens is upgraded to 40MP; equipped with 5100mAh battery + 88W fast charging + 50W wireless fast charging, the screen adopts Kunlun glass, and the back cover adopts island design.

　　It can be seen that the Huawei P60 is also true in comparison with the P60 Pro and P60 Art. The main differences are concentrated in the rear camera configuration and battery life charging configuration, but the price difference between them is very significant.

　　The P60 starts with 128GB of storage and is priced at 4488 yuan; the top storage is 512GB and priced at 5988 yuan.

　　The P60 Pro starts with 256GB of storage and is priced at 6988 yuan; the top storage is 512GB and priced at 7988 yuan.

　　The P60 Art starts with 512GB of storage and is priced at 8988 yuan; the top storage is 1TB and is priced at 10,988 yuan.

　　Overall, the Huawei P60 has undergone a relatively obvious upgrade in terms of performance, screen, body and image, and has become the most upgraded standard model of the Huawei P series over the years. Whether it is compared with the previous generation model P50, or compared with its other flagship Mate 50, or compared with the same series of high-end models, it has shown a quite good cost performance. Combined with the starting price of 4488 yuan, the Huawei P60 is obviously the most cost-effective and most worthwhile model in the P60 series.

　　The above is the Huawei P60, Huawei P60Pro and Huawei P60Art, which one is better? The details of the horizontal reviews of the three mobile phones.

Original title: Huawei P60, Huawei P60Pro and Huawei P60Art, which one is better, the three mobile phones are horizontally reviewed

Editor in charge: Li Xiaoling

Ruan Jingtian’s acting ＂Epilepsy＂ peak, high-scoring suspense action movie ＂Zhou Chu, except for the three evils＂ will be released on March 1

Directed and written by Huang Jingfu and starring Ruan Jingtian, and starring Yuan Fuhua, Chen Yiwen, Wang Jing, Li Liren and Xie Qiong, the high-scoring suspense action movie "Removing the Three Evils in the Week" has been announced and will be released nationwide on March 1. The film currently has a rating of 8.0 on Douban and 7.6 on IMDb. Ruan Jingtian, who plays the protagonist Chen Guilin, has been widely praised in the film. All kinds of emotions are freely controlled, and the martial arts scenes are punched to the flesh, earning enough audience expectations.

Ruan Jingtian's acting "Epilepsy" peak, high-scoring suspense action movie "Zhou Chu, except for the three evils" will be released on March 1

The allusions are fascinating, and the cast is highly anticipated

"Getting rid of the three evils around" tells the story of the wanted criminal Chen Guilin who thinks his life is about to end, so he decides to get rid of the two criminals ahead of him on the most wanted list and make a name for himself. The movie uses the allusions of "The Biography of Zhou Chu" in "Jinshu · Zhou Chu" and "Shishuoxinyu". It is recorded that the young man Zhou Chu is burly and powerful, but he runs amok in the countryside and is hated by his neighbors. Later Zhou Chu killed the tiger and evil dragon alone, and he himself turned his prodigal son back and changed his ways, so that all three evils are eliminated. The hearty and exciting fighting scenes in the film, the story of the protagonist Chen Guilin chasing the murderer for thousands of miles, controlling evil with evil, and the discussion of good and evil, crime and punishment are all highlights of the film. The acting skills of the star Ethan Ruan who can stand the test of the big screen, the intense performances of the powerful actors Yuan Fuhua, Chen Yiwen, Li Liren and others, and the appearance of the hair salon owner Xiaomei played by the popular actor Wang Jing are all highly anticipated. The film has performed well at the box office when it was released in Taiwan recently.

Ruan Jingtian's acting "Epilepsy" peak, high-scoring suspense action movie "Zhou Chu, except for the three evils" will be released on March 1

The action scenes are intense and burning, and the love-hate entanglements are fully displayed

In the final poster, the wanted criminal Chen Guilin, played by Ruan Jingtian, is unkempt and slovenly, with his hands cuffed and his hands pointed at a gun, but he laughs wildly and attracts curiosity. In the trailer released for this release, the audience was able to see the high-fire scenes of the film. Chen Guilin’s pursuit and fight in a narrow alley with police Chen Hui, the confrontation with Aberdeen, and the bizarre encounter in the New Mind Society caused adrenaline to soar, and the inexplicable ambiguity between Guilin and Xiaomei also tugged at the heartstrings of the audience. It is also worth mentioning that the three animals in the English title of the film "The Pig (Pig), The Snake (Snake) and The Pigeon (Pigeon) " The pig, the snake and the pigeon are derived from Buddhist concepts. In Buddhism, pigeons, snakes, and pigs are usually used to represent the three poisons of greed, hatred, and ignorance. In the film, pigs, snakes, and pigeons represent the three most wanted criminals. What kind of grievances and entanglements exist between the three, how the story of Chen Guilin’s pursuit of the murderer will unfold, and how the showdown between the two forces will end. Audiences and friends may wish to go to the cinema to find out when the movie is released.

Ruan Jingtian's acting "Epilepsy" peak, high-scoring suspense action movie "Zhou Chu, except for the three evils" will be released on March 1

A group of people in a dress, the description has been automatically generated

The film "Zhou Zhuan in addition to the three evils" is introduced by the Chinese film group company, the Chinese film joint stock company issued, star alliance film industry (Beijing) Co., Ltd. to assist in the promotion, online banking international film and television joint stock company, weilai TV network joint stock company, Liuliu Xixi joint stock company, Kaohsiung people, Perak international multimedia joint stock company, Taichung shooting, reproduction image production joint stock company, yellow people Co., Ltd., an attitude film joint stock company produced.

Little diva Jolin Tsai lost weight for love and praised her boyfriend Jinrong for her perfect figure

Jolin Tsai is about to publish a new book

Jolin Tsai appeared at the press conference

　　　 From the baby fat at the time of her debut to the now graceful little diva Jolin Tsai, every time is full of topics. Now she wants to publish a book on her slimming experience, but it has not been officially sold, and it has attracted attention from the outside world. Jolin Tsai published the slimming book "Raising Thin", which first fed 50,000 copies. She held a press conference on July 7 to celebrate her success. At the press conference, she revealed the slimming secret recipe for the first time. In the book, Jolin Tsai said that she was not born thin, but in order to be an artist, she still had to endure the stumbling process of slimming down. It was not until two years ago that she found a nutritionist and learned the correct way to lose weight that she lost weight and became healthy and beautiful.　

　　　 Jolin Tsai once confessed that the hell-style weight loss method made her body in a bad condition, with menstrual stagnation and even hair loss. She also knew that this kind of weight loss would not last long, so she began to listen to the nutritionist’s opinion. In addition, she interacted with Jinrong and ate no more than water. Jolin also confessed to discussing with Jinrong how to do health exercises, and also said that Jinrong was in good shape and did not need to lose weight. His shy appearance revealed the sweetness of love. Jinrong attended the watch endorsement and said at the press conference that he would send the other half to the watch. When asked, Jolin snickered and did not respond, only saying that he had not received any Valentine’s Day gifts.

More live pictures on the next page!

It is said that Wang Zuxian became a monk in Canada and was suspected of being stimulated by the scandal between Qi Qin and Xiao Qiang (Photo)

　　According to Hong Kong media reports, yesterday (July 7), news came out that Wang Zuxian, who has been away for a long time, is a monk in Canada. Friends said that she may be stimulated by the scandal between Qi Qin and Xiao Qiang earlier. And she has not been in touch with Qi Qin for a while.

Wang Zuxian, profile picture

　　Yesterday (July 7), there was news that Wang Zuxian, who had been out of the movie for a long time, was ordained in Canada. The reporter called Wang Zuxian’s friend Du Huidong to verify the matter. He said: "In recent years, Wang Zuxian has indeed been submerged in Buddhism. There is also a nunnery near where she lives, but I haven’t contacted her for a long time, so I don’t know the authenticity of the news. However, it is likely that she was stimulated by the news that her ex-boyfriend Qi Qin and Xiao Qiang may get married this year. In addition, when she was filming" Dream in the Garden ", she originally had expectations, but in the end her reaction was just ordinary. When her love and career were not very good, she cut her hair to become a nun."

　　In addition, Wang Zuxian’s friends, Miss Wang, Shi Nansheng, and Yang Fan, the director of "Dream in the Garden", told the media yesterday (July 7) that they had not heard of the news and had not contacted Wang Zuxian for some time. As for Qi Qin, there are reports that he thinks Wang Zuxian has always been submerged in Buddhism. If this continues, it is possible to become a monk. He also called Wang Zuxian when he went to Canada last month, but unfortunately he could not find her, so he has not contacted Wang Zuxian for some time.

　　Wang Zuxian’s relationship was quite rough. In the early years, she first dated Qi Qin, and then fell in love with a married wealthy businessman. Because her love with the wealthy businessman was not approved by the other party’s mother, she was also publicly abused, so she finally decided to cut off the love, return to Taiwan and get back together with Qi Qin, and prepared to get married in 1999. However, when even the banquet was booked, it suddenly broke out that Qi Qin had lived with a woman for many years and had flesh and blood, which caused the marriage to fail. Wang Zuxian was also heartbroken and went to Vancouver, Canada to live in seclusion. (fish/text)

The top ten investment and financing cases in the primary market in 2023： semiconductors attract the most money, and industrial capital and state-owned assets carry the weight

2023 is about to come to an end. Looking back on the first-tier market investment and financing this year, the overall cold atmosphere remains the same. There are more projects than money, and it is difficult to find top gifters for valuation declines, but there are also a few "Aoxue cold plums" dotted throughout the winter.

The Securities Times reporter combined the execution data (by financing amount) to sort out the top ten investment and financing cases in the primary market in 2023. Almost all of these companies that received large financing were concentrated in the field of semiconductors and new energy vehicles, especially the top semiconductor companies still have a huge ability to attract money. In addition, industrial capital and national funds have become the main top gifters behind these large financing cases.

Which companies are the most "gold-sucking" in 2023? Let’s see the following.

01, JITA Semiconductor completed 13.50 billion yuan financing

In August 2023, Shanghai JITA Semiconductor Co., Ltd. (referred to as "JITA Semiconductor") completed a 13.50 billion yuan financing. This round of financing brings together a number of national funds, industrial investors, local funds, and well-known financial investors. According to public information, JITA Semiconductor is a characteristic process integrated circuit chip manufacturer, focusing on the research and development and manufacturing of characteristic production processes required for analog circuits and power devices. The chips produced by BCD, IGBT/FRD, SGT/MOSFET, TVS, SiC devices are widely used in automotive electronics, industrial control, power management, intelligent end points, and even high-end app stores such as rail transit and smart grids.

It is worth mentioning that JITA Semiconductor also introduced Dr. Zhang Rujing, known as the "father of China’s semiconductor industry development", as an executive director in 2022. It is reported that JITA Semiconductor has built two plants in Lingang New Area and Xuhui District of China (Shanghai) Free Trade Pilot Zone, with a total capacity of 280,000 pieces built and under construction, and has made significant progress in the 12-inch automotive chip project.

02, Runpeng Semiconductor received 12.60 billion yuan capital increase

In August 2023, China Resources Microelectronics Co., Ltd. announced that its subsidiary Runpeng Semiconductor (Shenzhen) Co., Ltd. intends to increase capital and expand shares and introduce external investors such as the second phase of the National Integrated Circuit Industry Investment Fund Joint Stock Company. After the transaction is completed, Runpeng Semiconductor’s registered capital will increase from 2.40 billion yuan to 15 billion yuan, of which China Resources Microelectronics plans to increase investment 2.575 billion yuan this time, and the equity ratio of Runpeng Semiconductor held will decrease to 33%; the second phase of the big fund plans to increase investment 3.75 billion yuan, holding 25%, the second phase of the China state-owned enterprise structural adjustment fund plans to increase investment 1.50 billion yuan, holding 10%.

According to public information, Runpeng Semiconductor was established in June 2022 and is a power chip developer. The company’s business includes integrated circuit design, mask manufacturing, wafer manufacturing, packaging and testing, and discrete devices. It is mainly responsible for the construction of China Resources Microelectronics Shenzhen 300mm integrated circuit production line project, focusing on the simulation characteristic process above 40nm. The products are mainly used in automotive electronics, new energy, industrial control, consumer electronics and other fields. At present, Runpeng Semiconductor is still in the construction period and has not yet generated operating income.

03, Nezha Auto received 7 billion RMB crossover round financing

In August 2023, Nezha Automobile announced that it had completed a crossover round of financing totaling 7 billion yuan. Nezha Automobile is one of the leading new car manufacturers in China. In 2022, Nezha Automobile’s annual sales reached 152,000 vehicles, ranking first among new car manufacturers. In the first seven months of 2023, 72,500 vehicles were delivered, down 6.11% year-on-year.

Data show that from September 2017 to July 2022, Nezha Automobile received multiple rounds of financing. In July last year, Nezha Automobile announced the completion of the D3 round of financing, with a financing amount of more than 3 billion yuan; in addition to the previous D1 round and D2 round of financing, Nezha Automobile’s D round has accumulated financing of nearly 10 billion yuan. There are many companies and institutions investing in Nezha Automobile, including Ningde Times, Shenzhen Venture Capital, 360 Group, Huading Capital, Zhihe Travel, etc.

04, Huasheng New Energy received B + C round of financing over 5 billion yuan

In November 2023, Huasheng New Energy announced the completion of over 2 billion yuan C round of financing, led by China Green Hair Investment Group, Bank of China Assets and China Post Insurance, Wuxi Guolian Financial Investment Zhiyuan and emerging assets continued up the ante. As early as January this year, Huasheng New Energy has received over 2 billion yuan B round of financing. Two months later, Hongtai Fund announced its participation in Huasheng New Energy’s B + round of financing. So far, the total size of B series financing exceeds 2.40 billion yuan, and the post-money valuation 10 billion yuan. That is to say, Huasheng New Energy has received over 5 billion yuan in financing in 2023.

Founded in 2020, Huasheng New Energy mainly deploys silicon-based heterojunction solar technology research and development and large-scale production of products. According to the official website, one year after its establishment, Huasheng New Energy’s HJT cell monolithic efficiency exceeded 25.26%. By the end of 2022, Huasheng HJT production capacity had reached 2.7GW, accounting for nearly a quarter of the total market. In September 2023, Huasheng New Energy announced that it had achieved a company-wide operating profit. It is worth noting that Huasheng New Energy has announced its listing plan in September last year. It plans to start share reform in August 2023, and strive to start IPO filing in 2024.

05, Haichen Energy Storage completed the C round of over 4.50 billion yuan financing

In July 2023, Xiamen Haichen Energy Storage Technology joint stock company (referred to as "Haichen Energy Storage") completed the C round of financing, with a total amount of financing exceeding 4.50 billion yuan. This financing was jointly led by Guoshou Equity and Financial Street Capital, and was jointly led by Bank of China Assets, Jinshi Investment, SDIC Investment, China Venture Capital Fund, CICC Capital, CDH Baifu, and Sino-US Green Fund. First Construction Investment New Energy, Hefei Industrial Investment and existing shareholders Fenghe Capital, Jingwei Venture Capital, Agricultural Bank International, China Bing National Investment and other follow-up investments. According to industry sources, Haichen’s post-money valuation exceeded 30 billion yuan this round.

Haichen Energy Storage was established in 2019. The company is mainly engaged in the research and development, production and sales of lithium battery core materials and lithium iron phosphate energy storage batteries and systems. At present, the company’s products include square batteries, round batteries, battery modules and battery clusters, which can be widely used in household storage, base stations, photovoltaics, wind power, grid side, industrial and commercial energy storage and other scenarios. It has been 5 years since its establishment, and the company has completed 6 rounds of financing. At the same time, the company’s class A share IPO coaching was officially opened in July this year, with Huatai United Securities as its coaching agency.

06, Changfei Advanced Semiconductor completed over 3.80 billion yuan A round of financing

In June 2023, Anhui Changfei Advanced Semiconductor Co., Ltd. announced the completion of over 3.80 billion yuan A round of equity financing, with new investors including Optics Valley Financial Holdings, Fuzhe, Zhongping Capital, China Building Materials New Materials Industry Fund, CICC Capital’s funds (CICC SAIC, CICC Ruiwei, CICC Zhixing, CICC Qihe), Haitong M & A Fund, Guoyuan Financial Holdings Group’s funds (Guoyuan Equity, Guoyuan Fund, Guoyuan Innovation), Luxin Venture Capital, Dongfeng Assets, CCB Trust, October Capital, Hua’an Jiaye, Zhonghu Zhiyun, Baoyue Qicheng, Yunxiu Capital, etc.

Changfei Advanced focuses on silicon carbide (SiC) power semiconductor Product Research & Development and manufacturing. It can produce 60,000 6-inch SiC MOSFETs or SBD epitaxial and wafers, 6.40 million power modules, 18 million power single tubes, and currently can provide 650V to 3300V SiC SBD, SiC MOSFET related products. Changfei Advanced has now started the construction of the second base in "Wuhan · China Optics Valley". The investment scale of the first phase of the project exceeds 6 billion yuan, and the total investment of the project is expected to exceed 20 billion yuan. The first phase of the project will be completed in 2025. It will become the largest domestic silicon carbide production capacity (annual output 360,000 silicon carbide wafers), a complete packaging production line, and an integrated new highland including epitaxial growth and cutting-edge innovation centers.

07, Avita Technology completed the B round of 3 billion yuan financing

In August 2023, Changan Automobile announced that Avita Technology announced the completion of the B round of financing, the proceeds raised 3 billion yuan, and the post-money valuation was nearly 20 billion yuan. After the completion of this capital increase, Changan Automobile’s shareholding ratio remained unchanged at 40.99%, and Ningde Times held 14.1%, ranking second. In this round of financing, Changan Automobile, Southern Assets, Liangjiang Industrial Fund, etc. continued to increase investment, and also introduced Chongqing Industrial Fund of Funds, Bank of Communications Investment, Guangkai Holdings and other state-owned capital.

Avita Technology was established in July 2018, formerly known as Changan NIO, a joint venture between Changan Automobile and NIO, and changed its name to Avita Technology Company in May 2011. At present, Avita Technology has delivered more than 12,000 vehicles. Although it is not much among new energy vehicle companies, the company has been deeply bound to Huawei and Ningde Times. In August this year, Avita Technology announced that it will become the first batch of new energy vehicle brands equipped with Ningde Times Shenxing super-charged batteries, and Avita 11 Hongmeng Edition has also been listed.

08, YiSiWei calculates the completion of over 3 billion yuan D round of financing

In June 2023, Beijing Yisiwei Computing Technology Co., Ltd. (referred to as "Yisiwei Computing") announced the completion of the D round of financing of over 3 billion yuan. This round of financing was led by Financial Street Capital, Guoxin Venture Capital jointly led the investment, Yizhuang Guotou, Ruicheng Fund, China-Singapore Fund, Yixing Fund, Guangfa Qianhe, Jiantou Investment, Guangzhou Industrial Investment Group, National Integrated Circuit Industry Investment Fund Phase II, Yuncong Technology, Juhu Dream, Chuxin Fund, Caiyuan Capital, ultra-high definition Industrial Fund and other institutions followed suit.

The head of Yisiwei Computing is Wang Dongsheng, who is known as the "father of China’s semiconductor display industry". Since its establishment in 2019, the company has taken the RISC-V computing autonomous architecture as the core of its development. It has now formed a full-stack platform that integrates software and hardware with RISC-V. It is a new generation of computing architecture chip and solution provider with RISC-V. RISC-V is an Instruction Set Architecture architecture based on a streamlined Instruction Set Architecture architecture that can improve the performance and programmability of computers. In the context of cloud computing and AI explosion, it is highly sought after by enterprises. At present, RISC-V is in its infancy globally, and Chinese enterprises are in the first echelon in ecological construction. It is also seen by domestic manufacturers as an opportunity for domestic chip overtaking. In terms of hardware, Yisiwei Computing has completed the development of a series of 32-bit embedded core processors and applied them to dozens of self-developed chip products; the series of 64-bit processor cores has been verified, and related chip products will be used in multimedia, edge computing, wearable devices and other scenarios.

09, Xinwangda battery received more than 2.40 billion yuan in financing

In February 2023, Xinwangda announced that its holding subsidiary, Xinwangda Electric Vehicle Battery Co., Ltd. (referred to as "Xinwangda Battery"), received investment from 19 investors, spending a total of 2.43 billion yuan, and obtained about 19.5% of the equity of Xinwangda Battery. Investors include Li Auto, SAIC Group, GAC Group and other car companies. Based on this calculation, the current valuation of Xinwangda Battery is about 12.40 billion yuan. After the completion of this capital increase, Xinwangda is still the controlling shareholder of Xinwangda Battery, with a shareholding ratio of 57.5%.

According to the previous disclosure of Xinwangda, Xinwangda Battery has received orders for power batteries for a number of new models such as SAIC-GM Wuling and Dongfeng Liuqi, and has also carried out business cooperation with Renault-Nissan Alliance, Geely, Dongfeng Liuqi and other car companies. According to the data of China Power Battery Industry Innovation Alliance, from January to November 2023, Xinwangda Power Battery installed 7.24GWh, with a market share of 2.13%, ranking sixth in China.

10, Suiteng Juchuang through G series financing over 1.10 billion yuan

In April 2023, Suiteng Juchuang completed the G-1 series of 400 million yuan financing, and the G-2 series of 790 million yuan financing was completed at the same time, raising a total of 1.19 billion yuan twice. Suiteng Juchuang was founded in 2014 and is committed to promoting the large-scale commercialization and popularization of lidar. It is the only enterprise in the world that has realized the mass production and delivery of intelligent solid-state lidar car specifications. It has received fixed orders for more than 40 mass-produced models from BYD, GAC Aian, Weimar Automobile, Jitu, Lotus Technology, Yingche Technology, Zhitu Technology and other projects.

A few days ago, Suiteng Juchuang has launched a global prospectus and will be listed on the Hong Kong Stock Exchange on January 5, 2024. According to the prospectus, Suiteng Juchuang has received many financing since its establishment. Suiteng Juchuang completed C series financing in 2019, with a total scale of 250 million yuan; completed D series financing in December 2020, with a total amount of nearly 4 billion yuan so far. The investors participating in its new round of strategic financing include Yutong Group, Hubei Xiaomi Yangtze River Industrial Fund, Hong Kong Lixun Co., Ltd., Geely Holding Group; Lotus Technology, BAIC Group, GAC Group, BYD Group, Desai West Wei, as well as China Renaissance, Yunfeng Fund, Kunzhong Capital, Jinglin Investment, Chenling Capital, a number of funds under Oriental Fuhai, Kang Chengheng, Zhongxin Sunac and Xingshao Venture Capital, etc.

Editor in charge: Yue Yanan

Proofreading: Wang Wei

The 2024 Medici Innovative Drug Industry Ecological Cooperation Conference was a complete success

On March 18, the Medici Innovative Pharmaceutical Industry Ecological Cooperation Conference with the theme of "20 Years of Beauty, Creating the Future Together" was successfully held in Shanghai Zhangjiang Science Hall. After 20 years of hard work, Medici (688202) has taken empowering biomedical innovation research and development as its mission, grown side by side with China’s biomedical industry, and has developed into a leading one-stop biomedical pre-clinical R & D service platform in China.

At the conference, more than 500 industry leaders from various fields such as government, industry, academia, and finance gathered to participate in the grand event. Together, they reviewed Medisi’s outstanding history over the past 20 years, witnessed the launch of its globalization prelude, and the grand launch of two key technology service platforms. In addition, the conference also held a number of thematic dialogues around current hot topics. The guests brainstormed and discussed in depth the future development direction of the innovative drug industry ecology. They offered suggestions for the sustainable development of the industry, pointed out the way forward, and worked together to explore new opportunities for the cooperative development of Chinese pharmaceutical companies.

Twenty Years of Prosperity　Starting from "New" with high hopes

First of all, Mr. Wu Qiang, member of the Standing Committee of the Shanghai Pudong New Area District Committee and deputy head of the district, delivered a warm opening speech, expressing his heartfelt congratulations on Medici’s brilliant achievements over the past 20 years. He deeply reviewed how Medici participated in and witnessed the rapid development of the biomedical industry in Pudong, established an academician innovation drug ripening center, was approved by large enterprises to open an innovation center, and made outstanding contributions to the construction of the new drug empower ecosystem, and eagerly looked forward to Medici’s ability to continue to expand the breadth and depth of the industry and promote the vigorous development of the biomedical industry more widely. Finally, Vice Mayor Wu Qiang said that Pudong New Area will unswervingly promote institutional reform, provide a broader development space and more powerful policy support for the biomedical industry, and call on entrepreneurs and investors to come to Pudong to join hands in creating a new future of technological innovation!

Song Ruilin, executive chairperson of the China Pharmaceutical Innovation Promotion Association, pointed out in his speech that in the context of the reshaping of the global economic structure and the increasingly complex geopolitical situation, China’s biomedical industry is standing at a critical crossroads, facing both unprecedented challenges and huge development opportunities. In recent years, with the successive introduction of a series of policy plans, China’s biomedical industry has ushered in an unprecedented spring breeze of development, while Medicis and others will usher in a more rapid development momentum and contribute more to the rise of the biomedical industry. Finally, President Song Ruilin confidently emphasized that 2024 will be a year of hope for the biomedical industry.

Chen Chunlin, founder and CEO of Medici, expressed his sincere gratitude to all the guests in his speech. He mentioned that Medici has been fortunate to witness the rise of China’s biomedical industry and has achieved outstanding results in scientific research innovation, industrial integration and business expansion. He stressed that the current biomedical industry is ushering in a new spring, full of unlimited opportunities. As an important part of new drug research and development, Medici shoulders the important task of promoting the implementation of source innovation and empowering the development of the industry. Dr. Chen said that Medici looks forward to working with more partners to jointly build an ecological empowering circle and promote the sustainable innovation and development of the biomedical industry.

Chen Kaixian, an academician of the Chinese Academy of Sciences, delivered a wonderful keynote report, entitled "Biomedical R & D Innovation and Industrial Development", which deeply analyzed the opportunities and challenges of biomedical innovation and development, and comprehensively sorted out the situation, progress and problems of biomedical development in our country. He elaborated on the four major development trends of global pharmaceutical innovation, and keenly pointed out the shortcomings and bottlenecks in the field of biomedical development in our country. At the same time, Academician Chen also shared the hot spots of scientific and technological innovation, especially the application of artificial intelligence in the field of new drug research and development, which brought dawn to the research and development of new drugs. Finally, we look forward to strengthening cooperation from all walks of life and contributing to Shanghai’s goal of building a source of biomedical technology innovation and a world-class biomedical industry cluster.

The prelude to globalization has begun, deeply empowering the transformation of innovation achievements

Next, the prelude to a new chapter of globalization was officially opened, and the Transformation Ceremony of Medici’s Biomedical Source Innovation Achievements opened. This landmark moment not only fully demonstrates Medici’s outstanding innovation achievements in the field of biomedicine, but also indicates that these achievements will be quickly transformed into strong actual productivity, injecting new vitality and momentum into global cooperation and development, and enabling the drug research and development industry chain to innovate at the source and extend globally!

At the ceremony, Pharma representative Zhang Lianshan, research institute representative Li Bin, CXO industry representative Chen Chunlin, Zeng Dewan, Rong Yiping, AI intelligent medicine representative Zhang Long, overseas Biotech representative Mr. Sam Waksal, domestic Biotech representative Cheng Changfu, Liu Binlei, investor representative Zhao Yongsheng came to the stage one after another to join hands to start the transformation of biomedical source innovation achievements. Medici will take this launch ceremony as an opportunity to further strengthen communication and cooperation with domestic and foreign partners, jointly explore new paths for the transformation of biomedical innovation achievements, and work together to promote the sustainable prosperity and development of the global biomedical industry, and jointly create a better future.

Next, Mr. Sam Waksal shared his views on the original innovation of the biopharmaceutical industry and the globalization of innovative drugs, saying that under the leadership of Dr. Chen, Medici has developed over the past two decades and has become a leader in the industry, and its achievements are remarkable. Although the biomedical industry is young, it has shown great potential and influence on a global scale, driving sustained economic growth. Today, the pharmaceutical and biotechnology fields are closely linked, and they are jointly committed to the research and development of innovative drugs. Medici has played a pivotal role in it, not only transcending national borders and politics, but also injecting new vitality into the global economy. Finally, we look forward to the future to continue to witness their greater contributions to human health and economic development.

Innovative drug going overseas strategy and successful case sharing

Innovative drugs continue to go overseas, how to seize the global market? Under the chairpersonship of Qiangjing, founder & chairperson of Xinnuowei and founding partner of Xingze Capital, Zhang Lianshan, deputy general manager and president of global R & D of Hengrui Pharmaceutical, Xue Tongtong, founder, chairperson and CEO of Yilian Bio, Peng Jianbiao, president of Jimin Trustworthy Small Molecular Innovation Research Institute, Pan Wensen, partner of the Hong Kong office of Gaowin International Law Firm, and Lin Qingcong, executive vice president and president of the US company of Medici, industry leaders gathered together to discuss the strategy and path of innovative drugs going overseas.

Zhang Lianshan, Xue Tongtong, and Peng Jianbiao shared their respective strategic plans and successful experiences in innovative drugs going overseas from the perspective of pharmaceutical companies. They elaborated on how to achieve global distribution of innovative drugs through precise positioning, technological innovation, and international cooperation, providing useful inspiration for pharmaceutical companies.

From the legal perspective, Penvenson deeply analyzed the legal challenges and coping strategies faced by innovative drugs going overseas. He emphasized the importance of compliance and provided practical legal advice to the participants.

As an investor and a representative of pharmaceutical companies, Qiangjing shared Xinnovi’s unique experience in innovative drug research and development and internationalization, and said that Xingze Capital has been paying attention to the research and development and industrialization of innovative drugs, providing funds and resources for potential enterprises and projects, and promoting the globalization process of China’s innovative drugs.

Lin Qingcong shared the rich experience and profound lessons of Medici in assisting pharmaceutical companies to enter the international market from the perspective of CRO. He emphasized that Medici’s one-stop biomedical pre-clinical R & D service platform can support the whole process of drug discovery from target discovery to IND declaration. In addition, the new drug empower ecosystem of the Academician Innovative Drug Ripeness Center can help new drug funding, transactions and other issues. At present, Medici has established a research and development base in Boston, which will further empower the drug to go overseas and achieve higher value.

Multi-site blockbuster unveiling　Two key technology platforms released

At this grand ceremony, Medici’s two major science and technology platforms made a major appearance, attracting extensive attention from the participants.

1. Drug Discovery & Pharmaceutical Research Science Key Technology Platform

Jian Liu, President of Medici’s Drug Discovery and Pharmacy Research Division, introduced the Drug Discovery & Pharmacy Research Science Key Technology Platform. The platform includes a new drug platform for targeted protein degradation, a small nucleic acid drug development platform, an ADC drug development platform, a polypeptide macrocyclic peptide drug development platform, an AI drug development platform, a synthetic biology platform, a green chemistry platform, a drug metabolite platform, etc., to support the innovation of various drug forms. It is worth noting that Medici has a complete R & D platform for small molecule innovative drugs; an AI drug discovery platform empowers and accelerates new drug development from target discovery to the generation of preclinical compounds; a green chemistry platform and a synthetic biology platform enable the synthesis of various complex compounds.

2. Key technology platform for preclinical research science

Subsequently, Zhang Haizhou, president of Medici’s preclinical research division, elaborated on Medici’s key technology platform for preclinical research science. In terms of discovery biology, Medici has built in vitro screening platforms, such as PROTAC, small nucleic acids, ADC, etc., as well as cutting-edge technologies such as synthetic biology and nano-antibody discovery. In terms of pharmacological efficacy, there are advanced platforms such as in vivo imaging, small animal surgical excision, and in vitro imaging. In addition, Zhang Haizhou focused on introducing DMPK and safety service platforms for various advanced drug types such as PROTAC, oligonucleotide, ADC, mRNA, and cellular immunity, as well as pre-clinical service platforms such as inhalation medication, ophthalmic medication, and topical medication.

The release of the two key technology service platforms not only fully demonstrates the outstanding strength and profound heritage of Medici in the field of biomedical pre-clinical research and development, but also provides a solid and powerful support for its future customers to better empower.

Industry leaders gather together　A new blueprint for biomedicine

Frontier technologies and industrial applications of drug discovery

How to promote the transformation of basic scientific research results in China? What are the future development trends? Ma Dawei, academician of Chinese Academy of Sciences and researcher of Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Tao Weikang, vice president and general manager of global innovative drug research and development of Qilu Pharmaceutical Group, Liu Dongzhou, general manager of CSO/Innovative Drug Global R & D Center of East China Pharmaceutical, Shen Hong, head and senior vice president of Roche China Innovation Center, and Xu Yaochang, chairperson and CEO of Yuyu Pharmaceutical, shared their insights from their respective fields. Liu Jian, president of Medici Drug Discovery & Pharmaceutical Research Division, moderated this keynote dialogue.

Faced with the difficulty of transforming basic research, Ma Dawei shared in depth the course of cooperation with Academician Medisi’s Innovative Pharmaceutical Refinement Center, believing that this cooperation has achieved remarkable results in the transformation of scientific and technological achievements, bringing a mutually beneficial and win-win situation to both parties. At the same time, Shen Hong, head of Roche China Innovation Center and senior vice president, also introduced the Roche Accelerator, the world’s first self-established and operated accelerator project. The project fully integrates Roche’s own resources and advantages, and provides start-ups with all-round support including funding channels, cooperation opportunities, R & D experience, and advanced experimental equipment in an agile and flexible way to help start-ups grow rapidly and promote the development and industrialization of innovative drugs.

Tao Weikang, Liu Dongzhou, Shen Hong, Xu Yaochang and other pharmaceutical company leaders, based on the practical experience of their respective companies, discussed in depth how to accurately grasp their own advantages and differentiate the layout of innovative drug industry pipelines. They stressed that each company should formulate R & D strategies according to its core competitiveness. Facing the ever-changing technological challenges and changing future development trends, they said that pharmaceutical companies need to maintain keen insight and keep up with the pace of industry development. In sharing, they not only showcased the fruitful results achieved by their respective companies in the field of innovative drugs, but also provided valuable experience and inspiration for the future development of China’s innovative drug industry.

Transformation of new technologies for preclinical research of innovative drugs

Under the chairpersonship of Peng Shuangqing, Chief Scientific Officer of Medici, an in-depth discussion on the transformation of new technologies in preclinical research of innovative drugs was launched. The conference focused on breaking through the model barriers in preclinical research, technology development trends, market demand and future challenges, achievement transformation, and multi-party linkage.

Xu Zengjun, the former chief scientist of the Drug Evaluation Center of the State Food and Drug Administration and the founder of AstraZeneca Medicine, deeply analyzed the multiple challenges of preclinical research, such as the lack of understanding of the principle, mechanism and predictive correlation between models and diseases, as well as drug regulatory issues. Xia Mingde, founder/chairperson/CEO of Innolake Pharmaceutical, deeply analyzed the key role of translational medicine in crossing the "valley of death" in new drug development, and also pointed out the key role of translational medicine in crossing the "valley of death". Dr. Wang Yaning, former director of the clinical pharmacology department of the US FDA and CEO of Langlai Technology, pointed out that the FDA is cautious about preclinical data. Although AI technology is applied, there is insufficient data. It is necessary to optimize methods, strengthen translational research and data cooperation to improve R & D efficiency. Wang Haisheng, founder/chairperson/CEO of Sihe Genomics, emphasized the importance of AI in understanding the structure of genes and RNA, and mentioned the challenge of genetic differences between animal models and humans and the attempt of new organoid technologies. Yang Xiaobao, founder/chairperson/CEO of Bioscience, shared his research and development experience in the field of protein degradation, emphasized the importance of safety evaluation in preclinical research, and mentioned that with the help of Medici’s one-stop preclinical service platform, they successfully obtained clinical approval in China and the United States. Finally, he emphasized the enlightenment of tracking the layout of large companies such as MNC for Biotech.

Following the glorious past, we will move towards a glorious tomorrow. This 20th anniversary celebration of Medici is not only a feast for a full house, but also a brainstorming that concerns the development of the next 20 years. In the past two decades, Medici has not only witnessed the magnificent development history of the industry, but also acted as a vanguard force driving the continuous upgrading of the industry. In the future, Medici will adhere to innovation, deepen the field of biomedical pre-clinical research and development, lead technological innovation, enrich the matrix of R & D service platforms, layout the global market, ride the wind and waves, and move forward in the next two decades! (CIS)

Proofreading: Wang Jincheng

Original See Xian Siqi – Ren Xianqi, there have been zero scandals since his debut, because his popularity is too high, there is no need to hype it

Ren Xianqi’s popularity in those days was a metaphor. It was to convert the popularity of the most popular small fresh meat through buying water army into real popularity. Multiplying by a few dozen, it should be the real traffic during his peak period.

After the hit of "Too Soft Heart", Ren Xianqi and Bug decided to keep up the good work. In 1998, the album "Love Like Pacific" shook the Chinese music scene again. The album contains a total of 10 songs, and 4 of them have become popular. They are "Sad Pacific", "I am a fish", "Ren Xiaoyao" and the most popular "The girl opposite looks over".

In 1999, Ren Xianqi first appeared on the TV stage and sang the new song "The Girl Opposite Look Over". The next day, the song was played in audio stores and campuses across the country, and until now the song is still a divine song for boys to confess. Ren Xianqi also directly surpassed the Four Heavenly Kings who were in the limelight at that time with the popularity of this album. Therefore, the TV series "Heroes of the Divine Condor" and "New Chu Liuxiang" all valued his popularity, and even forced him to play Yang Guo and Chu Liuxiang regardless of his appearance. This also has the classic quotation of netizens. He can play Yang Guo and Chu Liuxiang like that. Do you think he is red or not? After the movie "Star Language Wish" was released, many people cried.

Compared with the prosperity of his career, his feelings are very simple. No matter what era an artist is in, his career will be affected if he makes his love public, and Ren Xianqi was torn at first. In 2002, Ren Xianqi proposed to his girlfriend at a concert abroad, ending a 17-year long love run. This unknown woman finally waited for Ren Xianqi, who has become the king of Asia, to propose. And Ren Xianqi has also become a great man for his wife for decades. However, because of his busy career, he failed to give his wife a romantic wedding, which is also his biggest regret.

In 2004, he threw away his idol burden and played the villain in Du Qifeng’s "Big Event", which opened up his own drama path and was a great success. After that, he starred in "Fire Dragon Showdown", although he played the bad guy, it was not hated, and he was even called the best actor delayed by singing by netizens. In 2006, Ren Xianqi even held his own personal concert in the Internet People’s Great Hall.

Once a lot of people become popular, it is easy to lose themselves in fame and fortune, but Ren Xianqi is an exception. In 2007, Bug left Rolling Stone and founded his own company, but he took away nearly 10 million yuan in cash because of his unscrupulous accounting. Overnight, he went bankrupt and was heavily in debt, which many people avoided. Ren Xianqi learned about the situation of his mentor, and without saying a word, he went to his house with a million yuan in cash. Brother Bug took it and used it, but he didn’t need to return it. At that time, Bug was moved and said to Ren Xianqi, I will definitely return the money to you, but Ren Xianqi waved his hand. No matter what, I will help you. Without you, I would not be where I am today. When it comes to this matter, Guo Degang praised Ren Xianqi as someone who knows how to be grateful, but he said that this is the most basic.

Not only was he loyal to his friends, but Ren Xianqi also never forgot his roots. He had been born and raised in Taiwan since childhood. In fact, his ancestral home was Wuhan, Hubei. Once he went home to visit relatives, the traffic in Wuhan was not developed at that time, and the roads were also potholed. Then he paid for the construction of roads for his hometown, hoping to help the development and construction of his hometown. In addition, what Ren Xianqi is most fond of talking about is his support for Mayday. The Rolling Stones have always had the spirit of inheritance of old people and newcomers. Therefore, when Ren Xianqi was at his hottest, Li Zongsheng handed Mayday to him. Ren Xianqi not only did not hide all his singing and performance experience, whether it was participating in a performance or a concert, as long as there was a place to show his face, he took the trouble to introduce this newcomer band. A Xin, the captain of Mayday 2022, wrote a confession letter to their big brother Ren Xianqi on Weibo, thanking Qi Ge for covering us for more than 20 years.

More than 30 years after his debut, Ren Xianqi was a rare male god who had no scandals and zero bad reviews. Such a good man who was affectionate, righteous and responsible was worthy of the word "Xianqi" that his father had given him back then.

Responsible editor:

Intelligent Transportation ＂2.0＂： Putting ＂Brains＂ on the Road

　　Autonavi Maps has launched a "smart cone bucket" that applies the Internet of Things transformation. After connecting to its map app data platform, it can realize real-time collection and release of information such as road construction, accidents and closure controls, and improve user travel efficiency and safety. The picture shows that in January this year, a road construction information released by a "smart cone bucket" set in the Dinghu rest area of Guangfo Zhao Expressway has been uploaded to the map app. Photo by Liu Dawei, a reporter from Xinhua News Agency

　　Have you seen the "brain" of road traffic? What kind of scenario does the future of smart travel look like? In fact, before we know it, the "brain" of traffic has already been "bravely leading the beam" between the endless roads, empowering a more technological way of travel.

　　In recent years, new technologies such as "Internet +", intelligent networking, big data, and artificial intelligence have been continuously applied in the field of road transportation, integrating more and more deeply into people’s lives, and constantly meeting people’s new expectations for safe, convenient, and high-quality travel. At the same time, "black technology" has gradually been applied, innovating and enriching the new connotation of "smart transportation", which also echoes the deep-seated needs of cities to improve their comprehensive transportation management capabilities.

　　Recently, under the guidance of the Traffic Administration of the Ministry of Public Security, the "2019 Internet + Urban Traffic Management Innovation Forum" jointly sponsored by the China Road Traffic Safety Association and Autonavi Map was held in Hefei. Experts in the field, public security traffic management departments, universities and scientific research institutions, and representatives of related industries and enterprises from all over the country gathered together to share innovative services and technological achievements in the transportation industry, and make suggestions for the comprehensive realization of intelligent transportation. It also showed a vivid and colorful future travel picture.

　　"Black technology" escorts road safety

　　The data shows that with the in-depth implementation of China’s transportation power strategy, the transportation industry has developed rapidly, and the road for people and vehicles has continued to grow at a high speed. As of the end of June this year, the number of motor vehicles in the country has reached 340 million, of which 250 million cars, 66 cities in the country have more than 1 million cars, 29 cities have more than 2 million cars, and 11 cities such as Beijing and Chengdu have more than 3 million cars. Under the rapid growth, it also puts forward higher requirements on how to apply big data and serve traffic control.

　　car recognition

　　According to Sun Zhengliang, party secretary of the Traffic Management Science Research Institute of the Ministry of Public Security, in recent years, the construction of the highway traffic safety prevention and control system has continued to advance, and the network of bayonets, video and law enforcement forensics equipment has been connected to the public security traffic integrated command platform. It is expected that traffic surveillance video will be "networked nationwide" by the end of this year.

　　At the same time, 25 kinds of illegal analysis models and vehicle characteristics database were established to screen all kinds of illegal acts from the traffic trajectory data. The successful application of the integrated command platform has also made the deck car invisible. By labeling the vehicle "portrait", the integrated command platform can analyze 470 billion track data, screen out more than 120,000 suspected fake deck cars, and re-screen those with higher frequency. After the data is synchronized with provinces and cities, the fake deck is locked through cross-regional spatiotemporal analysis.

　　Face recognition

　　Not only is it "recognizing the car", but through facial recognition technology, the platform can also accurately detect relevant license-related violations in real time, and accurately "recognize the face". License-related violations are mostly divided into three categories: driving without a license, losing driving (Note: traffic violations in which drivers still drive motor vehicles on the road after losing their driving qualifications, such as "drunk driving" revoking their driver’s license, "drug driving" canceling their driver’s license, "super score" not learning, overdue inspection, etc.) and permitted driving do not match. In fact, it is far from enough for such personnel to enforce the law through the traffic police. It is very difficult. The application of facial recognition technology can use data comparison, analysis and judgment to systematically warn and deal with the behavior of lost drivers on the road.

　　Mobile navigation becomes a traveler’s "all-round guide"

　　The development of "smart +" travel and the improvement of travel efficiency with "seamless" travel services will reduce the average travel time and layered travel mode, and use the traffic design foundation and transportation tools to drive the travel industry into the stage of intelligent transportation development. Liu Zhenfei, partner of Alibaba and president of Autonavi Maps, said that the management and service travel mode with mobile navigation applications as the breakthrough point will open up all levels, allowing travelers to receive comprehensive and efficient services "before the trip", "during the trip" and "after the trip".

　　The era of smart travel is coming, and mobile navigation can play a role far more than just "guiding the way". It is transforming into an inseparable "all-round guide" for travelers.

　　Protect safety

　　"There are tens of thousands of roads, and safety comes first." Dynamic traffic incident voice prompts are the link between managers and travelers. Mobile navigation receives dynamic traffic cloud information in real time and prompts travelers at any time. Through the application of the "smart cone bucket" after the transformation of the Internet of Things, road construction information can be uploaded to the map app, connected to the data platform to realize real-time collection and release of road construction, accidents and closed control information, and set up safety barriers. With the appearance of the "smart cone bucket", the secondary accident rate of Shanghai-Nanjing Expressway alone has been reduced by 34%.

　　improve efficiency

　　Taking Autonavi maps as an example, according to the analysis results of KPMG and the National Research Institute of Economics, mobile navigation applications save users at least 1.90 billion hours of congestion time, greatly improving traffic efficiency and fuel efficiency. And like the "multi-directional real-time road conditions" first launched in the industry last November, it realizes lane-level navigation at intersections and guides vehicles at intersections more accurately.

　　guard the environment

　　"By gradually launching’real-time public transportation ‘and other green travel navigation, we are transforming into a mobile navigation application for multi-mode green travel." According to Liu Zhenfei, in the past year, more than 37% of users have adopted green travel mode, and the proportion of green travel sharing has even exceeded that of cities with perfect public transportation services, such as Toronto, Canada, and Brisbane, Australia. "In the past few years, by improving our technical capabilities, we have not only made map navigation tools, but also hoped to provide a large number of new products and services for green travel in the whole city. We have launched’smart bus stations’, covering more than 10 cities. Travelers can effectively plan travel time through vehicle information inquiry, and public travel will become more and more convenient." Liu Zhenfei said.

　　Drawing alluring future travel scenarios

　　In July this year, the Ministry of Transport officially issued the "Digital Transportation Development Plan Outline", proposing to build a digital collection system, a networked transmission system and an intelligent application system with the "data link" as the main line, and accelerate the development of transportation informatization to digitalization, networking and intelligence, providing support for the construction of a transportation power.

　　City CT

　　Congestion, excessive resource consumption, traffic accidents… How to solve the urban traffic problem? At the forum site, the Autonavi map mirror system was officially launched. In the opinion of Dong Zhenning, vice president of Autonavi maps, the "mirror" that realizes intelligent analysis, evaluation and diagnosis of urban traffic based on AI and big data is like the "CT" of the city. It scans the factors affecting urban traffic in multiple dimensions, provides the "medical report" of urban traffic operation, and analyzes the reasons, so as to provide the basis for accurate and comprehensive policies.

　　After obtaining the "diagnosis result", the next step is to focus on realizing the information coordination of people, cars and roads and establishing a service model that quickly reaches users. In Wuhan, Autonavi maps have been coordinated with the information of signal lights. In addition, when congestion, accidents and other situations occur, video AI recognition technology can judge the perceived road conditions in the first time, and realize zero-hour diversion guidance through intermediaries such as apps, in-car navigation, and smart guidance screens.

　　One-stop, full chain

　　"One-stop" and "full chain" are undoubtedly the direction of change in future travel services. Qiu Hongtong, a researcher at the Institute of Traffic Management Science of the Ministry of Public Security, believes that the new demand for travel can be explained from three aspects: managers, service providers, and travelers. Managers can use big data tools to correctly guide travel services and better supervise new business models; service providers have the ability to provide reservation-based and customized services; travelers can better adapt to and enjoy the continuous changes in travel methods.

　　Open data, policy guidance, technical support and effective supervision. In the process of achieving the goal of future smart travel, there are still several key issues to be solved. Liu Zhenfei said that in the future, "smart +" travel will be further promoted in four aspects: automation, electrification, networking and sharing, deepen cooperation among enterprises, and deepen innovation in basic applications.

　　"Start with travel, integrate with life", the process of intelligent upgrade of the platform is also a process of open resource sharing and data integration. Only by working hard to get out of the "data island" can the digital dividend better benefit everyone.

　　(Reporter, Sun Yahui)

Hengda’s Tianjin factory is temporarily suspended, and the cumulative delivery of Hengchi 5 is less than 1,000 vehicles

　　China Economic Net April 26th (reporter, Guo Yue) April 24th, Hengda Automobile (stock code: 00708.HK) announced that the company will sell its 47 health space projects to China Hengda Group at a price of 2 yuan, in order to focus more on the development of new energy vehicles. The announcement also disclosed that due to lack of funds, Hengda Tianjin factory has temporarily suspended production of Hengchi 5, and is expected toMayResume production.

　　Specifically, Hengda Automobile said that the sale of the health space project is due to the huge capital demand involved in the new energy vehicle project, coupled with the current situation of Hengda Group, so continuing to invest resources in the health space project is not in line with the group’s overall deleveraging strategy, and may also limit the development of new energy vehicles. The company hopes to achieve more focused and professional development of new energy vehicles by reducing its holdings of non-main business assets.

　　The announcement also said that due to insufficient funds, Hengda’s Tianjin factory will temporarily suspend production of Hengchi 5 and is expected toMayResume production. According to Hengda Automobile’s announcement on March 22, as of the announcement date, the company has delivered more than 900 Hengchi 5 vehicles to users.

Chen Turin exposed the behind-the-scenes of ＂Hua Qiangu＂ Weiya drama, Li Chengbin confessed to Huo Jianhua

1905 movie network news　On the evening of January 19th,The fantasy-themed film premiered in Beijing. Producer Tang Lijun, director, starring,,,,, and others appeared at the post-screening meeting, sharing the feelings of participating in the creation of classic IP changes.

The movie "Hua Qiangu" is adapted from the novel of the same name, telling the story of the girl Hua Qiangu’s struggle with fate all the way, finally finding herself and harvesting pure love. As the main creator of the drama version and the film version, producer Tang Lijun said in an interview at the premiere that he hoped that this sincere work could bring new touches to the audience: "I hope that the growth story of Hua Qiangu will not only convey the emotion of human nature to the audience, but also want to show the growth and transformation of women, and be brave to be themselves." Director Zhang Chaoli also talked about the original intention of taking this work, and admitted that he was also deeply stressed at the moment, hoping to gain the audience’s recognition.

At the premiere, several of the stars of "Hua Qiangu" also shared the behind-the-scenes stories of the shooting, as well as their understanding of the story and characters. Chen Turin, who plays the heroine Hua Qiangu, said that after watching the story, she felt that "Hua Qiangu" could resonate with many girls, which is also what moved people in this story. She also revealed that as a "fear of heights" patient, the shooting of this Weiya drama made a deep impression on herself, and even the star even vomited after the shooting, and everyone paid a lot for the wonderful performance.

Actor Li Chengbin also shared his preparations for playing the character of Baizihua from the outside to the inside. In addition to being a vegetarian, slimming down, practicing meditation, and studying the Four Books and Five Classics, he is also very clear about the audience’s expectations for Baizihua in front of the version of Zhuyu. At the premiere, Li Chengbin also confessed that in his mind, Huo Jianhua is a god-like existence: "I hope everyone will show mercy [to me]."

It is reported that the movie "Hua Qiangu" officially landed in theaters on January 20, sharing with the audience the fantasy story of "Hua Qiangu going against the wind all the way".